KYOTO A panel of experts from the Ministry of Health approved a clinical research program proposed by a team from the University of Kyoto on Friday for the transplantation of cartilage from induced pluripotent stem cells [iPS] into damaged knee joints.

Professor Noriyuki Tsumaki and other members of the team are planning to produce 2 to 3 millimeter diameter cartilage using iPS cells, which will be stored at the Universitys Center for iPS Cell Research and Application [CiRA].

The team plans to perform the first transplant this year. According to a clinical study by Asahi Kasei Corp., which supports the project, the technology should be put into practice in 2029.

Four people between the ages of 20 and 70 are transplanted with iPS cell cartilage for their damaged knee joints, with the damage range between 1 cm and 5 cm. The team does not plan to seek additional patients for the program.

Immunosuppressors are not used in the transplant because cartilage usually does not show an immune response.

The team will monitor the four patients for possible tumor development for a year after the operation. If the operations are successful, the transplanted material melts into the existing cartilage.

There are many patients who experience discomfort from cartilage damage, said Tsumaki at a press conference at Kyoto University Hospital on Friday. We will work hard to offer therapy methods.

The team will also try to apply the therapy to patients with osteoarthritis.

In 2014, Riken, a research institute affiliated with the Japanese government, transplanted retina cells made from iPS cells to treat an incurable eye disease in the worlds first transplant of iPS-derived cells.

Similar transplants were later performed by Kyoto University for Parkinsons and Osaka University for corneal diseases.

Follow this link:
The Kyoto University team's plan to transplant iPS cartilage into knee joints is OK - gotech daily

IPS Cell Therapy Comments Off on The Kyoto University team’s plan to transplant iPS cartilage into knee joints is OK – gotech daily | January 25th, 2020

US Stem Cell (OTCMKTS:USRM) and National Research (NASDAQ:NRC) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, analyst recommendations, valuation, earnings, risk, institutional ownership and profitability.

Earnings and Valuation

This table compares US Stem Cell and National Researchs revenue, earnings per share and valuation.

Insider and Institutional Ownership

39.7% of National Research shares are owned by institutional investors. 16.7% of US Stem Cell shares are owned by company insiders. Comparatively, 4.5% of National Research shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Risk and Volatility

US Stem Cell has a beta of 4.87, suggesting that its share price is 387% more volatile than the S&P 500. Comparatively, National Research has a beta of 0.78, suggesting that its share price is 22% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for US Stem Cell and National Research, as reported by MarketBeat.com.

Profitability

This table compares US Stem Cell and National Researchs net margins, return on equity and return on assets.

Summary

National Research beats US Stem Cell on 7 of the 9 factors compared between the two stocks.

US Stem Cell Company Profile

U.S. Stem Cell, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of autologous cellular therapies for the treatment of chronic and acute heart damage, and vascular and autoimmune diseases in the United States and internationally. Its lead product candidates include MyoCell, a clinical therapy designed to populate regions of scar tissue within a patient's heart with autologous muscle cells or cells from a patient's body for enhancing cardiac function in chronic heart failure patients; and AdipoCell, a patient-derived cell therapy for the treatment of acute myocardial infarction, chronic heart ischemia, and lower limb ischemia. The company's product development pipeline includes MyoCell SDF-1, an autologous muscle-derived cellular therapy for improving cardiac function in chronic heart failure patients. It is also developing MyoCath, a deflecting tip needle injection catheter that is used to inject cells into cardiac tissue in therapeutic procedures to treat chronic heart ischemia and congestive heart failure. In addition, the company provides physician and patient based regenerative medicine/cell therapy training, cell collection, and cell storage services; and cell collection and treatment kits for humans and animals, as well operates a cell therapy clinic. The company was formerly known as Bioheart, Inc. and changed its name to U.S. Stem Cell, Inc. in October 2015. U.S. Stem Cell, Inc. was founded in 1999 and is headquartered in Sunrise, Florida.

National Research Company Profile

National Research Corporation (NRC) is a provider of analytics and insights that facilitate revenue growth, patient, employee and customer retention and patient engagement for healthcare providers, payers and other healthcare organizations. The Companys portfolio of subscription-based solutions provides information and analysis to healthcare organizations and payers across a range of mission-critical, constituent-related elements, including patient experience and satisfaction, community population health risks, workforce engagement, community perceptions, and physician engagement. The Companys clients range from acute care hospitals and post-acute providers, such as home health, long term care and hospice, to numerous payer organizations. The Company derives its revenue from its annually renewable services, which include performance measurement and improvement services, healthcare analytics and governance education services.

Receive News & Ratings for US Stem Cell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for US Stem Cell and related companies with MarketBeat.com's FREE daily email newsletter.

More:
Contrasting National Research (NASDAQ:NRC) and US Stem Cell (NASDAQ:USRM) - Slater Sentinel

Cardiac Stem Cells Comments Off on Contrasting National Research (NASDAQ:NRC) and US Stem Cell (NASDAQ:USRM) – Slater Sentinel | January 25th, 2020

Irving Weissman and Joseph McCune, Opinion contributors Published 7:00 a.m. ET Jan. 24, 2020

Severe Trump administration restrictions mean millions of Americans of all political and religious stripes won't benefit from fetal tissue research.

Last summer the Trump administration curtailed federal funding of medical research using human fetal tissue; the new rulestook effect Oct. 1. More recently, the administration addedrestrictions that are even more severe.

Immediately, important work at two NIH-supported labs in Montana and California that are fighting the AIDS epidemic stopped because they were testing new medications against HIV using mice with human immune systems derived from human fetal tissue. In the near term, all National Institutes of Health (NIH) funding of research using fetal tissuewill likely cease.

More than 30years ago, we invented SCID-hu mice for biomedical research on diseases affecting humans, by implanting human fetal blood-forming and immune system tissuesinto mice whose immune systems had been silenced. The implanted immune tissues came from an aborted fetus, and allowed our otherwise immune-deficient mice to exist and be vulnerable to viruses that infect humans.

Tissues from living infants would not have worked;they are too far along in development and nearly impossible to obtain. This mouse model (and later versions of it) became the only living system, outside of a human, in which advanced therapies for diseases like AIDS and other viral infections could be evaluated before they were given to people.

Our work with human fetal tissue proceeded with the highest level of caution and vigilance. We received advice from bioethicists, clergyand government officials, which led to the establishment of strict guidelines that are still used today. No woman was asked or paid to terminate a pregnancy, the termination process was unaltered, and the women were asked for donation of the organs only after they had decided to terminate the pregnancy. Thus, obtaining the fetal tissue for medical research had no impact on ending pregnancies.

Since then, mice with transplanted human fetal tissues have been successfully used by scientists to identify blood stem cells and to devise treatments now availableor in clinical trialsfor cancer, various viral infections, Alzheimers disease, spinal cord injuries, and other diseases of the nervous system. Such diseases kill or cripple many Americans including pregnant women, fetusesand newborn infants. Many of them have only a short window of opportunity wherein a new therapy can treat them, and a delay can be fatal.

National Institutes of Health in Bethesda, Maryland, on Oct. 21, 2013.(Photo: *, Kyodo)

The Trump administration's new rules are tantamount to a funding ban. In academic labs, the experiments are done by students and fellows in training, and the new rules block any NIH-funded students or fellows from working with human fetal tissue. Those who imposed the banmust bear responsibility for the consequences: People will suffer and die for lack of adequate treatments.

Americans pay the price:Trump administration's 'scientific oppression' threatens US safety and innovation

At a December 2018 meeting at NIH,after hearing scientific evidence about alternative research methods such as the use of adult cells, experts concluded that the use of fetal tissue is uniquely valuable. Nonetheless, the administration severely restricted the use of fetal tissue, thereby denying millions of Americans the fruits of such research Americans of all political stripes, since deadly viruses and cancers do not care who you vote for.

These restrictions subvert the NIH mission, which is to advance medicine and protect the nations health. To the extent that it was motivated by the religious beliefs of those in charge, it bluntly transgresses the American principle of separation of church and state. As a result, both believers and non-believers will die.

Of course, all who take the Hippocratic Oathto "do no harm,"which includes all medical doctors, will always offer and deliver all types of therapies that are available.

Restricting science: Trump EPA's cynical 'transparency' ploy would set back pollution science and public health

However, we believe that thoseresponsible forthis de facto ban, and perhapsthose who agree with them, should personally accept its consequences. We challenge them tobe true to their beliefs. They should pledge to never accept any cancer therapy, any AIDS medication, any cardiac drug, any lung disease treatment, any Alzheimers therapy, or any other medical advance that was developed using fetal tissue including our mice. Its a long list, one that you can learn about from us here. Should this apply to you, be faithful and be bold: Take the pledge.

Irving Weissman is a Professor of Pathology and Developmental Biology and the Director of the Stanford Institute of Stem Cell Biology and Regenerative Medicine and Ludwig Center for Cancer Stem Cell at Stanford University School of Medicine. Joseph McCune is Professor Emeritus of Medicine from the Division of Experimental Medicine at the University of California, San Francisco. The views expressed here are solely their own.

Autoplay

Show Thumbnails

Show Captions

Read or Share this story: https://www.usatoday.com/story/opinion/2020/01/24/trump-fetal-tissue-research-ban-hurts-all-americans-column/4553379002/

Go here to read the rest:
If you want to ban fetal tissue research, sign a pledge to refuse its benefits - USA TODAY

Cardiac Stem Cells Comments Off on If you want to ban fetal tissue research, sign a pledge to refuse its benefits – USA TODAY | January 25th, 2020

EL PASO, Texas -- Biomedical research scientists from Texas Tech University Health Sciences Center El Paso and The University of Texas at El Paso are partnering up to send "artificial mini-hearts" to the International Space Station to better understand how microgravity affects the function of the human heart.

The three-year project, funded by the National Science Foundation (NSF) and the space station's U.S. National Laboratory, brings together TTUHSC El Paso faculty scientist Munmun Chattopadhyay, Ph.D., and UTEP biomedical engineer Binata Joddar, Ph.D. The researchers will collaborate in their Earth-bound labs to create tiny (less than 1 millimeter thick) heart-tissue structures, known as cardiac organoids, using human stem cells and 3D bioprinting technology.

By exposing the organoids to the near-weightless environment of the orbiting space station, the researchers hope to gain a better understanding of a health condition known as cardiac atrophy, which is a reduction and weakening of heart tissue. Cardiac atrophy often affects astronauts who spend long periods of time in microgravity. A weakened heart muscle has difficulty pumping blood to the body, and can lead to problems such as fainting, irregular heartbeat, heart valve problems and even heart failure. Cardiac atrophy is also associated with chronic disease.

The first year of the project, which began in September, will focus on research design. During this phase, Dr. Joddar will use 3D printing to fabricate the cardiac organoids by coupling cardiac cells in physiological ratios to mimic heart tissue. The second year will be centered on preparing the organoid payload for a rocket launch and mission in space. The third and final year of the research will involve analyzing data from the experiment after the organoids are returned to Earth.

The project will also provide an educational opportunity for the El Paso community, with a workshop for K-12 students to learn about tissue engineering projects on the space station. It will also include a seminar for medical students, interns and residents about the benefits and challenges of transitioning research from Earth-based laboratories into space.

Read the original here:
El Paso scientists team up for heart research project at the International Space Station - KVIA El Paso

Cardiac Stem Cells Comments Off on El Paso scientists team up for heart research project at the International Space Station – KVIA El Paso | January 25th, 2020

The blood collected from the umbilical cord of the newborn is a rich source of stem cells. This blood is collected and sent to a cord blood bank, where the stem cells are separated, tested, processed, and preserved in liquid nitrogen. Technically, there is no expiry date and these stem cells can be preserved for a lifetime. Scientifically, evidence exists that they can be stored for about 20 years. The stem cells can treat around 70 blood related disorders and genetic disorders including thalassemia, sickle cell anaemia, leukaemia, and immune related disorders.

Stem cells taken from umbilical cord blood are like those taken from bone marrow, capable of producing all blood cells: red cells, platelets and immune system cells. When used, stem cells are first concentrated, then injected into the patient. Once transfused, they produce new cells of every kind.

They're capable of producing all types of blood cells: red cells, platelets and immune system cells. The stem cells can treat around 80 blood related illnesses like leukaemia, lymphomas, several genetic conditions and immune related disorders. But given the present state of medicine, they are effective only for around a dozen of them

See the article here:
Watch | Stem cell banking and its benefits - The Hindu

Bone Marrow Stem Cells Comments Off on Watch | Stem cell banking and its benefits – The Hindu | January 25th, 2020

Poland has emerged as Europe's leader in stem cell storage, a billion-dollar global industry that is a key part of a therapy that can treat leukaemias but raises excessive hopes.

Submerged in liquid nitrogen vapour at a temperature of minus 175 degrees Celsius, hundreds of thousands of stem cells from all over Europe bide their time in large steel barrels on the outskirts of Warsaw.

Present in blood drawn from the umbilical cord of a newborn baby, stem cells can help cure serious blood-related illnesses like leukaemias and lymphomas, as well as genetic conditions and immune system deficits.

Polish umbilical cord blood bank PBKM/FamiCord became the industry's leader in Europe after Swiss firm Cryo-Save went bankrupt early last year.

It is also the fifth largest in the world, according to its management, after two companies in the United States, a Chinese firm and one based in Singapore.

Since the first cord blood transplant was performed in France in 1988, the sector has significantly progressed, fuelling hopes.

- Health insurance -

Mum-of-two Teresa Przeborowska has firsthand experience.

At five years old, her son Michal was diagnosed with lymphoblastic leukaemia and needed a bone marrow transplant, the entrepreneur from northern Poland said.

The most compatible donor was his younger sister, Magdalena.

When she was born, her parents had a bag of her cord blood stored at PBKM.

More than three years later, doctors injected his sister's stem cells into Michal's bloodstream.

It was not quite enough for Michal's needs but nicely supplemented harvested bone marrow.

As a result, Michal, who is nine, "is now flourishing, both intellectually and physically," his mum told AFP.

A cord blood transplant has become an alternative to a bone marrow transplant when there is no donor available, with a lower risk of complications.

Stem cells taken from umbilical cord blood are like those taken from bone marrow, capable of producing all blood cells: red cells, platelets and immune system cells.

Story continues

When used, stem cells are first concentrated, then injected into the patient. Once transfused, they produce new cells of every kind.

At the PBKM laboratory, "each container holds up to 10,000 blood bags... Safe and secure, they wait to be used in the future," its head, Krzysztof Machaj, said.

The bank holds around 440,000 samples, not including those from Cryo-Save, he said.

If the need arises, the "blood will be ready to use without the whole process of looking for a compatible donor and running blood tests," the biologist told AFP.

For families who have paid an initial nearly 600 euros ($675) and then an annual 120 euros to have the blood taken from their newborns' umbilical cords preserved for around 20 years, it is a kind of health insurance promising faster and more effective treatment if illness strikes.

But researchers also warn against unrealistic expectations.

- Beauty products -

Haematologist Wieslaw Jedrzejczak, a bone marrow pioneer in Poland, describes promoters of the treatment as "sellers of hope", who "make promises that are either impossible to realise in the near future or downright impossible to realise at all for biological reasons."

He compares them to makers of beauty products who "swear their cream will rejuvenate the client by 20 years."

Various research is being done on the possibility of using the stem cells to treat other diseases, notably nervous disorders. But the EuroStemCell scientist network warns that the research is not yet conclusive.

"There is a list of almost 80 diseases for which stem cells could prove beneficial," US haematologist Roger Mrowiec, who heads the clinical laboratory of the cord blood programme Vitalant in New Jersey, told AFP.

"But given the present state of medicine, they are effective only for around a dozen of them, like leukaemia or cerebral palsy," he said.

"It's not true, as it's written sometimes, that we can already use them to fight Parkinson's disease or Alzheimer's disease or diabetes."

EuroStemCell also cautions against private blood banks that "advertise services to parents suggesting they should pay to freeze their child's cord blood... in case it's needed later in life."

"Studies show it is highly unlikely that the cord blood will ever be used for their child," the network said.

It also pointed out that there could be a risk of the child's cells not being useable anyway without reintroducing the same illness.

Some countries, such as Belgium and France, are cautious and ban the storage of cord blood for private purposes. Most EU countries however permit it while imposing strict controls.

- Rapid growth -

In the early 2000s, Swiss company Cryo-Save enjoyed rapid growth.

Greeks, Hungarians, Italians, Spaniards and Swiss stored blood from their newborns with the company for 20 years on payment of 2,500 euros upfront.

When the firm was forced to close in early 2019, clients were left wondering where their stem cells would end up.

Under a kind of back-up agreement, the samples of some 250,000 European families were transferred for storage at PBKM.

The Polish firm, founded in 2002 with two million zlotys (around 450,000 euros, $525,000), has also grown quickly.

Present under the FamiCord brand in several countries, PBKM has some 35 percent of the European market, excluding Cryo-Save assets.

Over the last 15 months, outside investors have contributed 63 million euros to the firm, PBKM's chief executive Jakub Baran told AFP.

But the company has not escaped controversy: the Polityka weekly recently published a critical investigative report on several private clinics that offer what was described as expensive treatment involving stem cells held by PBKM.

Read the original here:
Europe's guardian of stem cells and hopes, real and unrealistic - Yahoo News

Bone Marrow Stem Cells Comments Off on Europe’s guardian of stem cells and hopes, real and unrealistic – Yahoo News | January 25th, 2020

Gray hair got you down? Scientists may have a cure for that.

Okay, maybe not a cure. But, more information about why youre going gray, and what can be done about it.

Dr. Melissa Harris, an assistant professor at the University of Alabama at Birminghams Department of Biology, has spent the last ten years studying melanocyte stem cells and what happens when they fail.

Harris runs a molecular biology lab at UAB and uses CRISPR gene editing tools, single-cell sequencing studies, and network analysis algorithms. She uses gray hair as a model for aging, because she doesnt always need a microscopeshe can see the state of your melanocyte stem cells right away. If hair is all one color, Harris said, the melanocyte stem cells are healthy; but if there are grays mixed in, something isnt right.

Gray hair isnt always an inevitable part of aging, the university said. Through Harris research, shes learned that age isnt the only reason these cells fail, and now Harris is working with gray-haired mice to show there could be a way to bring the cells- and hair pigments- back to life. Shes doing that by working with a biotech startup to study an experimental compound that appears to restore hair color long-term in those mice.

Harris work applies to autoimmune diseases and to melanoma, but she said her primary goal is to understand why somatic stem cells (those found in muscles, bones, and organs that are responsible for tissue regeneration, immune defense, hair color and more) start to fail as a person ages. Most of those stem cell populations are hard to work with in the lab, Harris said, but melanocyte stem cells are an exception.

Does hair graying cause you to die? Harris said. No, you can watch melanocyte stem cells from birth to the end. But, she added that the same cant be said for cells like hematopoetic stem cells, which pump red blood cells in bone marrow. You cant live long without them, Harris said.

Her research will reveal more about the bodys aging process and the life cycles of those stem cells.

Harris is often known as the gray-hair lady in the lab, but she stresses that her gray hair research has bigger implications. Everyone gets gray hair It is considered a vanity science, she said. I am not an abnormally vain person My lab has picked the model that is the most appropriate method to investigate what happens to stem cells as we age.

The work has earned her a grant from the NIHs National Institute of Aging. A paper published by her lab in 2018 showed that MITF, a certain protein that is the master regulator turning on pigmentation genes also represses the innate immune system, according to UAB. The university said when Harris worked with the MITF-deficient mice with a virus, the melanocyte stem cells suffered and the mice got gray hair. The study was globally recognized, and featured in several publications.

Perhaps, in an individual who is healthy yet predisposed for gray hair, because they produce less MITF, getting an everyday viral infection is just enough to cause the decline of their melanocytes and melanocyte stem cells, leading to premature gray hair, Harris told UAB News.

Harris started working with the biotech startup when she was contacted by them last year. They were developing an experimental compound that would regrow hair, and they wanted to know if she would test it on her mice. Harris said she was skeptical, but she conducted a small trial.

It worked. Harris said when she tests gray-haired mice with the compound, she sees hair color come back.

Some gray hairs could be rejuvenated, the university said, through compounds to stimulate the cells. (Courtesy, UAB)

And we can take these same mice, pluck the hair and when new hairs grow out they retain the higher level of pigmentation, suggesting this is permanent, she said. This compound is reprogramming the stem cells, taking them to a younger state, allowing them to start up again.

Harris and Joseph Palmer, one of her doctoral students, are also studying a theory that the melanocyte stem cells spend most of their time in a dormant state, and that the cells can possibly be stimulated.

(Spanish doctors in a study) suggested that some melanocyte stem cells are retained in gray hairs, Harris said. We thought that once you go gray the stem cells are all lost theres no going back. But presumably they can be reactivated. That study means, according to Harris, there may be therapies to reactive the cells, and the compound shes working with alongside the startup could be a promising way forward, according to UAB.

We have an opportunity with this company to find out what are the potential ways we can fix a broken system, Harris said. Were always looking at whats broken and rarely do we get to go in the other direction, towards tissue rejuvenation. So this is exciting.

Read this article:
UAB scientist studies aging through gray hair, says hair could be rejuvenated - AL.com

Bone Marrow Stem Cells Comments Off on UAB scientist studies aging through gray hair, says hair could be rejuvenated – AL.com | January 25th, 2020

Many folks around the globe will be seen troubled by ache within the veins. And many occasions, even after an excessive amount of therapy, this ache just isnt relieved. But within the coming days you possibly can do away with neuralgia fully, that too with none unwanted effects. Researchers on the University of Sydney have used human stem cells for excessive ache aid in mice.

->Now, theyre shifting in direction of human trials.

Greg Nelly, senior researcher on the Charles Perkins Center, stated that at occasions, extreme strain on the nerves causes them to get broken. For instance, carpal tunnel syndrome is the median nerve within the arms ( median nerve ) Due to extreme strain. As you possibly can think about, nerve accidents can result in insufferable neuropathic ache. There can also be no efficient therapy to alleviate ache in most sufferers.

Therefore, Nelly and colleagues on the University of Sydney developed an efficient remedy. Researchers have been capable of create pain-relieving neurons utilizing human stem cells.

Nelly stated that this success implies that for some sufferers affected by nerve ache, we are able to carry out pain-relieving implants from our cells, which might cease the ache.

In the examine, researchers collected stem cells from grownup blood samples. Then, used human-induced pluripotent stem cells (iPSCs) from the bone marrow to create pain-relieving cells within the laboratory.

To check the efficacy of the therapy, the staff injected neurons that abolished spinal ache in mice affected by extreme neuropathic ache. It was revealed that this therapy supplied full aid from ache to the mice with none unwanted effects.

Co-senior creator Dr. Leslie Caron stated that which means that transplant remedy is more likely to be an efficient and long-lasting therapy for neuropathic ache.

After shut therapy in mice, the University of Sydney staff is shifting ahead for extra in depth research in pigs. Within the subsequent 5 years, theyll check people that suffer from power ache.

Researchers stated {that a} move check in people can be an enormous success. This might point out the event of latest non-opioid, non-addictive ache administration methods for sufferers.

Visit link:
Get rid of the ache within the nerves discovered with the following pointers, learn - Sahiwal Tv

Bone Marrow Stem Cells Comments Off on Get rid of the ache within the nerves discovered with the following pointers, learn – Sahiwal Tv | January 25th, 2020

The folk wisdom that tension and anxietycan turn your hair gray appears to be scientifically valid, according to a new study in mice.

Researchers found that the cascade of fight-or-flight hormones precipitated by stressful events eliminated many of the stem cells responsible for hair color in mice.

This group of stem cells, which have the ability to turn into many types of cells, are found in the base of each hair follicle and give hair its color by becoming pigment producing cells called melanocytes which produce brown, black, red and yellow colors in hair and skin.

The researchers found that stress causes these stem cells to convert into melanocytes en masse, only to drift away from the follicle and break down. This depletes the follicles supply and can mean the next time it makes a hair there arent enough stem cells to give it a color, producing an unpigmented gray or white hair.

After a series of experiments, the researchers narrowed down the culprit behind the destruction of the follicles pigment factories to the fight-or-flight hormone noradrenaline, or norepinephrine which is released by whats called the sympathetic nervous system.

Normally, the sympathetic nervous system is an emergency system for fight or flight, and it is supposed to be very beneficial or, at the very least, its effects are supposed to be transient and reversible, biologist Ya-Chieh Hsu, who led the study, told the New York Times.

This is the first scientific study explicitly linking stress and graying, according to Hsu.

The experiments in mice found that acute stress could wipe out all the melanocyte stem cells in just five days. Early tests suggest the same might be true in humans: When the researchers exposed human melanocyte stem cells to noradrenaline they too differentiated in large numbers.

Hsu told the Guardian the same response may drive age-related greying. There are definitely shared responses between how the melanocyte stem cells respond to stress and how they respond to aging, she said. You essentially lose the stem cell pool in aging as well.

Developing the research into an effective treatment to end graying hair will likely take years, but revealing the mechanism at work could advance our understanding of how stem cells are lost elsewhere in the body one of the hallmarks of the physical decline that accompanies aging.

This is certainly one implication that Im particularly excited about, biologist Christopher Deppmann, who was not involved in the research, told the Guardian. I believe that we have only scratched the surface of whether and how stress and fight-or-flight mechanisms deplete other stem cell populations. Whether or not this is the cause of premature aging remains to be determined, but I wouldnt bet against it.

Like any good study, it opens up at least as many questions as it answers, he added. But it may represent an important stepping stone toward rationalizing and developing pharmaceutical fountains of youth.

Read this article:
If you're worried about your hair turning gray, don't stress out! - The Hill

Skin Stem Cells Comments Off on If you’re worried about your hair turning gray, don’t stress out! – The Hill | January 24th, 2020

China started off 2019 by completing the first soft landing on the far side Earths moon. It was a monumental achievement, and the months since the mission arrived at the Moon have been filled with interesting discoveries, including the discovery of a strange gel-like substance around a lunar crater.

Now, as China celebrates the one year anniversary of the Change 4 lander and Yutu-2 rover arriving at the Moon, the countrys space group has released a wealth of data, including some never-before-seen images of the far side of Earths tiny neighbor.

The images some of which benefit from post-processing at the hands of talented scientists and enthusiasts show the Moons least-studied face in stunning detail.

Image Source: CNSA / TECHNIQUES SPATIALES

The Change 4 mission included a lunar lander and a rover that explored the Moons surface. Because of the nature of day and night on the Moon, the instruments are put into a sleep mode when the far side falls into shadow, waking back up when the sun shines again.

China, which has historically lagged behind countries like the United States and Russia when it comes to space exploration, is rapidly catching up. Landing on the far side of the Moon is no easy task, and the countrys space agency pulled it off with flying colors. Going forward, China is poised to be a major player in space exploration and has even discussed the possibility of setting up semi-permanent bases on the lunar surface.

You can browse through a massive collection of these new images via a handy Google Drive link, or sift through the raw images via CNSAs web portal.

Image Source: CNSA / Techniques Spatiales

Go here to read the rest:
China just released the most stunning images from the far side of the Moon - BGR

Skin Stem Cells Comments Off on China just released the most stunning images from the far side of the Moon – BGR | January 24th, 2020

(Photo: Stocksy)

You either swear by facial oils or are skeptical of all the fanfare and its myriad of purported benefits. In recent years, facial oils have become a booming skincare category, taking up prominent shelf space. There are all kinds of facial oils you can choose from with ingredients like rosehip, marula and jojoba. They are also said to boast a bevy of skincare benefits like brightening, calming inflammation and minimizing the look of fine lines and wrinkles. Despite their popularity, theres also some confusion around face oils. Will they clog pores? Do they replace your moisturizer? Do you even actually need one? To help make sense of it all, we enlisted the help of two experts to break it all down, plus, the best facial oils for every skin concern.

Read this next:The 20 Best Lip Balms to Save You From Dry Winter Hell

The purpose of a facial oil is to provide moisture to the skins surface and serve as a protective layer against environmental aggressors, says Dr. Monica Li, a Vancouver-based dermatologist and clinical instructor in the department of dermatology and skin science at the University of British Columbia. Facial oils both act like an emollient (filling in the gaps between skin cells to strengthen the outer layer)and an occlusive agent (sealing water in at the skin surface), explains Li.

Our skin produces natural oilsknown as sebumwhich help retain water within the skin surface. A facial oil is basically added protection, helping supplement the oils the skin already produces and maintain a robust skin barrier function, says Li.

A face oil can be a game-changer for your skin, says Jennifer Brodeur, a Montreal-based facialist to celebs like Oprah and Michelle Obama, and founder of JB Skin Guru. The right face oil will help with skin homeostasis [its ability to maintain a stable internal environment], as it provides nutrition and hydration to the skin.

Facial oils can be beneficial for everyoneeven oily skin types. A caveat: theres no one-size-fits-all formula. As not all face oils are created equally, its important to know what face oils are right for you, says Brodeur.

Since not all oils are the same, different ones will have different skincare benefits. Beyond its hydrating and nourishing properties, a facial oil can also have anti-inflammatory, antimicrobial and antioxidant benefits, depending on the ingredients and composition, says Li. Brodeur adds: My favourites are those that contain lots of good fatty acids and vitamins. For example, sunflower seed oil, peoni root extract and rosehip seed oil. However, you also need to be mindful of your skin type.

Read this next:I Hate That I Feel Like I *Have* to Wear Makeup

For sensitive skin, Brodeur recommends steering clear of essential oils, especially citrus oils. Essential oils can be very potent, which means they can cause irritation or trigger allergies for sensitive skin. Citrus oils in particular like orange, grapefruit and bergamot can cause photosensitivity, resulting in skin irritation or discolouration. Brodeur also suggests avoiding oils with dye or fragrances.

If you have oily skin, Dr. Li recommends using an oil with a light texture like jojoba or grapeseed that will absorb more easily into the skin and wont clog pores.

For dry skin, look for a facial oil with either oat or argan oil, both of which are known for their soothing and nourishing properties. Mixing two to three drops of the facial oil with a moisturizer will have a compounded hydrating effect, says Li.

Once you choose an oil, apply it on a test spot like on the wrist or behind the ears for at least a week. Keep in mind that these natural oil ingredients may be a source of contact allergens depending on the individual, she adds. Facial oils are still a relatively new category of skincare and more research and clinical studies are l needed, so its best to consult with a board-certified dermatologist if you have any questions or concerns.

Read this next:I Have Dry Acne-Prone Skin and This Is How I Deal in Winter

The answer will vary depending on who you ask (yes, its that controversial). For the most part, experts agree that you should use a facial oil after your moisturizer as the final step in your skincare routine. Oil sits on water, so it creates a protective layer to prevent water loss, explains Brodeur. However, if your skin is on the drier side, you can apply oil first or even layer with an oil, moisturizer and then oil again. You can even mix a few drops of facial oil into your moisturizer or foundation for a dewy glow.

As a rule of thumb, serums are usually used to target specific skin concerns [such as hyperpigmentation and fine lines and wrinkles], whereas oils are primarily used to nourish and hydrate the skin, says Brodeur, meaning you can use both a serum and a facial oil.

Always apply facial oil on clean skin after youve cleansed. Brodeur recommends using two to three drops and taking the time to massage it into your skin using upward strokes.

Inner Glow Face Oil, $120, amandinesolbotanicals.com

Formulated with a blend of botanicals and essential oils like lavender and calendula sourced from the founders family farm in Ontario, this multi-tasker lends a helping hand for a healthy, glowy complexion.

Lextrait, $225, jbskincare.com

Made with a concentrated blend of sunflower seed oil, peony root extract and licorice root, this gentle oil soothes and hydrates skin.

Rosehip BioRegenerate Oil, $50, shoppersdrugmart.ca

Rosehip seed oil does all the heavy lifting in this formula with vitamins, antioxidants and essential fatty acids, which help with brightening, collagen production and fighting free radicals.

Stem Cellular Vinifera Replenishing Oil, $90, sephora.com

Jojoba, macadamia and olive squalene oils help boost the skins moisture while fruit stem cells, vitamin C and grapeseed oil to help improve skin tone and radiance.

BIO Organic Lavandin Smooth & Glow Facial Oil, $23, walmart.ca

Tapping into lavandin essential oil (a hybrid created from true lavender and spike lavender) and argan oil, this formula promises smooth, supple skin with a non-greasy finish.

Squalane + Tea Tree Balancing Oil, $65, sephora.com

Ultra-hydrating and lightweight squalene meets skin-purifying tea tree oil for a nourishing and quick-absorbing face oil.

See the rest here:
The Best Facial Oils and How to Use Them - FLARE

Skin Stem Cells Comments Off on The Best Facial Oils and How to Use Them – FLARE | January 24th, 2020

New Delhi: On Saturday, January 18th, 2020, the Advancells Group & the International Fertility Center together ended their first workshop Sub-Specialty Training in Application of Regenerative Medicine (S.T.A.R. 2020). The three-day workshop had specialized doctors, medical practitioners, learned scientists of Advancells, the leaders in cell manufacturing & processes and IFC, one of Indias most prestigious Fertility institute who were joined by candidates with MBBS/BAMS/BHMS/BPharma & Masters degree in Life Sciences.

The key-note speaker of the workshop was Dr. Rita Bakshi, founder and chairperson of International Fertility Centre, the oldest fertility clinic and one of the most renowned IVF clinics in India, one of the organizers of the event. Participants also had a privilege to listen to Dr. Sachin Kadam, CTO, Advancells and gain hands-on experience in the preparation of PRP; Liposuction method; and Bone Marrow aspiration. All these techniques were talked about at length and demonstrated in the form of manual & kit-based models to help the candidates gain exposure.

Dr. Punit Prabha, Head of Clinical Research and Dr. Shradha Singh Gautam, Head of Lab Operations at Advancells successfully set the base of stem cell biology for the participants who were experts in gynecology field, stem cell research and pain specialist. With the help of detailed analysis of Application of PRP for Skin rejuvenation; Preparation of Micro-fragmented Adipose Tissue and Nano Fat & SVF (Stromal Vascular Fraction) from Adipose Tissue; and Cell Culturing and Expansion in a Laboratory, applicants understood the application of stem cells in aesthetics, cosmetology, and anti-aging.

Vipul Jain, Founder & CEO of Advancells Group said, Educating young scientists about stem cells is important for us. With this workshop we wanted to discuss and share the challenges and lessons we have learned in our journey of curing our customers. We wanted to establish more concrete knowledge base in the presence of subject matter experts and help our attendees in more possible ways. We are hopeful to have successfully achieved what we claimed with this workshop.

Given the resounding success of the Sub-Specialty Training in Application of Regenerative Medicine (S.T.A.R. 2020), its hoped that the future events shall offer even greater wisdom to the participants by helping them improve and the lead the community into the age of greater awareness.

Advancells Group Advancells is leading the field of stem cell therapies in India and abroad, with representative offices in Bangladesh and Australia. The company provides arrangements for stem cell banking and protocols for partner doctors and hospitals which they can use for treating the patients using regenerative medicine. With a GMP compliant research and processing center that works on different cell lines from various sources such as Bone Marrow, Adipose Tissue, Dental Pulp, Blood, Cord Tissue etc. Advancells also intends to file a patent for this processing technology soon.

For more information, visit https://www.advancells.com/

International Fertility Centre IFC is Indias leading fertility center under the leadership and guidance of Dr. Rita Bakshi. She along with her solid team of experienced doctors have create a network of 10+ IVF clinics located in India and Nepal. Their services include In-vitro Fertilization (IVF), Intrauterine Insemination (IUI), Intracytoplasmic Injection (ICSI), Egg Donation, Surrogacy, Blastocyst, Assisted Hatching, Hysteroscopy, Laparoscopy and much more.

More:
Advancells Group & IFC Concluded their 3-Day Workshop on Regenerative Medicine - India Education Diary

Skin Stem Cells Comments Off on Advancells Group & IFC Concluded their 3-Day Workshop on Regenerative Medicine – India Education Diary | January 24th, 2020

Chronic pain cost an estimated $139.3 billion in 2018. Image: iStock, Top image: Pexels

Researchers at the University of Sydney have used human stem cells to make pain-killing neurons that provide lasting relief in mice, without side effects, in a single treatment. The next step is to perform extensive safety tests in rodents and pigs, and then move to human patients suffering chronic pain within the next five years.

If the tests are successful in humans, it could be a major breakthrough in the development of new non-opioid, non-addictive pain management strategies for patients, the researchers said.

Thanks to funding from the NSW Ministry of Health, we are already moving towards testing in humans, said Associate Professor Greg Neely, a leader in pain research at the Charles Perkins Centre and the School of Life and Environmental Sciences.

Nerve injury can lead to devastating neuropathic pain and for the majority of patients there are no effective therapies. This breakthrough means for some of these patients, we could make pain-killing transplants from their own cells, and the cells can then reverse the underlying cause of pain.

Go here to see the original:
Pain treatment using human stem cells a success - News - The University of Sydney

Bone Marrow Stem Cells Comments Off on Pain treatment using human stem cells a success – News – The University of Sydney | January 24th, 2020

Poland has emerged as Europe's leader in stem cell storage, a billion-dollar global industry that is a key part of a therapy that can treat leukaemias but raises excessive hopes.

Submerged in liquid nitrogen vapour at a temperature of minus 175 degrees Celsius, hundreds of thousands of stem cells from all over Europe bide their time in large steel barrels on the outskirts of Warsaw.

Present in blood drawn from the umbilical cord of a newborn baby, stem cells can help cure serious blood-related illnesses like leukaemias and lymphomas, as well as genetic conditions and immune system deficits.

Polish umbilical cord blood bank PBKM/FamiCord became the industry's leader in Europe after Swiss firm Cryo-Save went bankrupt early last year.

It is also the fifth-largest in the world, according to its management, after two companies in the United States, a Chinese firm and one based in Singapore.

Since the first cord blood transplant was performed in France in 1988, the sector has significantly progressed, fuelling hopes.

Mum-of-two Teresa Przeborowska has firsthand experience.

At five years old, her son Michal was diagnosed with lymphoblastic leukaemia and needed a bone marrow transplant, the entrepreneur from northern Poland said.

The most compatible donor was his younger sister, Magdalena.

When she was born, her parents had a bag of her cord blood stored at PBKM.

More than three years later, doctors injected his sister's stem cells into Michal's bloodstream.

It was not quite enough for Michal's needs but nicely supplemented harvested bone marrow.

As a result, Michal, who is nine, "is now flourishing, both intellectually and physically," his mum told AFP.

A cord blood transplant has become an alternative to a bone marrow transplant when there is no donor available, with a lower risk of complications.

Stem cells taken from umbilical cord blood are like those taken from bone marrow, capable of producing all blood cells: red cells, platelets and immune system cells.

When used, stem cells are first concentrated, then injected into the patient. Once transfused, they produce new cells of every kind.

At the PBKM laboratory, "each container holds up to 10,000 blood bags... Safe and secure, they wait to be used in the future," its head, Krzysztof Machaj, said.

The bank holds around 440,000 samples, not including those from Cryo-Save, he said.

If the need arises, the "blood will be ready to use without the whole process of looking for a compatible donor and running blood tests," the biologist told AFP.

For families who have paid an initial nearly 600 euros ($675) and then an annual 120 euros to have the blood taken from their newborns' umbilical cords preserved for around 20 years, it is a kind of health insurance promising faster and more effective treatment if illness strikes.

But researchers also warn against unrealistic expectations.

Haematologist Wieslaw Jedrzejczak, a bone marrow pioneer in Poland, describes promoters of the treatment as "sellers of hope", who "make promises that are either impossible to realise in the near future or downright impossible to realise at all for biological reasons."

He compares them to makers of beauty products who "swear their cream will rejuvenate the client by 20 years."

Various research is being done on the possibility of using the stem cells to treat other diseases, notably nervous disorders. But the EuroStemCell scientist network warns that the research is not yet conclusive.

"There is a list of almost 80 diseases for which stem cells could prove beneficial," US haematologist Roger Mrowiec, who heads the clinical laboratory of the cord blood programme Vitalant in New Jersey, told AFP.

"But given the present state of medicine, they are effective only for around a dozen of them, like leukaemia or cerebral palsy," he said.

"It's not true, as it's written sometimes, that we can already use them to fight Parkinson's disease or Alzheimer's disease or diabetes."

EuroStemCell also cautions against private blood banks that "advertise services to parents suggesting they should pay to freeze their child's cord blood... in case it's needed later in life."

"Studies show it is highly unlikely that the cord blood will ever be used for their child," the network said.

It also pointed out that there could be a risk of the child's cells not being useable anyway without reintroducing the same illness.

Some countries, such as Belgium and France, are cautious and ban the storage of cord blood for private purposes. Most EU countries, however, permit it while imposing strict controls.

In the early 2000s, Swiss company Cryo-Save enjoyed rapid growth.

Greeks, Hungarians, Italians, Spaniards and Swiss stored blood from their newborns with the company for 20 years on payment of 2,500 euros upfront.

When the firm was forced to close in early 2019, clients were left wondering where their stem cells would end up.

Under a kind of back-up agreement, the samples of some 250,000 European families were transferred for storage at PBKM.

The Polish firm, founded in 2002 with two million zlotys (around 450,000 euros, $525,000), has also grown quickly.

Present under the FamiCord brand in several countries, PBKM has some 35 per cent of the European market, excluding Cryo-Save assets.

Over the last 15 months, outside investors have contributed 63 million euros to the firm, PBKM's chief executive Jakub Baran told AFP.

But the company has not escaped controversy: the Polityka weekly recently published a critical investigative report on several private clinics that offer what was described as expensive treatment involving stem cells held by PBKM.

More here:
Europe's guardian of stem cells and hopes, real and unrealistic - Deccan Herald

Bone Marrow Stem Cells Comments Off on Europe’s guardian of stem cells and hopes, real and unrealistic – Deccan Herald | January 24th, 2020

The tiny body seemed consumed by tubes and wires and monitors.

Just one day prior, Stephanie and Cody Smith had learned the terrible truth about why their 18-month-old son, Charlie, had been so sick recently. He had neuroblastoma, a cancer that forms on the nerve endings. Scans revealed cancer was on his kidney, lungs, bone and lymph nodes.

To stem the aggressive cancer, his doctors immediately got to work, putting in catheters, taking bone marrow biopsies and preparing for the start of intense chemotherapy. Charlie lay in his hospital bed eating Cheetos Puffs, his favorite food, and sitting with his parents.

"It was hard when we got the news," Stephanie Smith said. "I tried to be calm and collected; I had to be strong for my baby. But its been hard."

Story continues below gallery

The past two months have come straight out of a nightmare for the Smith family. Since Charlie was diagnosed with Stage IV neuroblastoma in November, each day brings uncertainty.

The Franklin family has spent 49 of the last 60 days at Riley Hospital for Children at IU Health. Charlie has gone through rounds of chemotherapy, suffering through fevers, mouth sores, extreme fatigue and nausea that wracked his small body. His treatment will last over the next 18 months, and will include chemotherapy, stem cell transplants, blood transfusions, radiation and immunotherapy.

But despite everything theyve been through, the Smiths remain resolute that Charlie will get better. They have relied on their faith, and an army of supporters who have stepped forward to help them in their worst time, to get them through.

"It was amazing to see so many people come up and love on us. It has taught us to be generous people; weve always thought we were generous people, but when you see the number of people who care for you and pray for you and support you, its really amazing," Stephanie Smith said.

The Smiths have partnered with Versiti Blood Center of Indiana to host a blood drive in Greenwood Saturday. The Cheering for Charlie event will be held from 6 a.m. to 2 p.m., to help increase blood supplies for patients such as Charlie who rely on transfusions to survive.

Every two seconds, someone needs life-saving blood, whether theyre bravely battling disease like Charlie, undergoing surgery or are victims of trauma," said Duane Brodt, spokesman for Versiti. "People need people since blood cant be manufactured."

For most of his life, Charlie was a happy-go-lucky toddler. He loved to smile and laugh, beaming joy. Where his 3-year-old brother Henry was more of a wild child, Stephanie Smith said, Charlie seemed to always be in a pleasant, good mood.

His parents described him as their "happy baby."

Thats what made his lethargy, lack of appetite and gradual decline in health so concerning.

"He was learning how to walk over the summer, and started getting sick," Stephanie Smith said. "We just thought it was a virus; we didnt think of the worst."

Charlie developed a low-grade fever, wasnt eating well and was falling asleep unexpectedly while playing with toys. He wasnt acting like himself, Stephanie Smith said.

During a visit to his pediatrician, the doctor found a hard area on Charlies abdomen, and recommended doing some blood tests and taking an X-ray. Those tests only led to more questions he had severe range anemia and elevated levels of platelets in his blood. But the doctor didnt have any conclusive answers as to what was causing it.

Stephanie Smith, a nurse at Franciscan Health, started hearing warning bells in her mind. That, combined with a mothers intuition, convinced her that they needed to take Charlie to Riley Hospital for Children. After 12 hours in the emergency room, and dozens of tests, doctors found a large tumor in Charlies abdomen.

"Sometimes, when kids are diagnosed with cancer, they can go home and be in and out of the hospital for treatment, but Charlie was really sick. The tumor was pushing on his kidney, damaging his kidney, so we had to stay in the hospital," Stephanie Smith said.

The pathology lab at Riley Hospital for Children confirmed the tumor was neuroblastoma. The cancer forms in immature nerve endings, often in the adrenal glands located near the kidneys and is most common in children age 5 and under, according to the American Cancer Society.

But the cancer is very rare; only about 800 new cases are diagnosed in the U.S. each year, according to the American Cancer Society.

Neuroblastomas grow and spread very rapidly, so treatment would have to be aggressive, doctors explained to the family. Charlies oncologist recommended starting with two rounds of focused chemotherapy, followed by the extraction of his red blood cells for stem cell transplants, then another three rounds of chemotherapy.

Two different stem cell transplants would be held about a month apart, and Charlie would start radiation treatment. Immunotherapy, which jolts the immune system into targeting and killing cancer cells, would be the final part of the regimen.

Almost immediately, Charlie started his chemotherapy.

"It grows so quickly, that we had to be aggressive. The beginning was pretty intense," Stephanie Smith said.

The treatment was hard on Charlies young body. He developed mouth sores and didnt want to eat, and his nausea left him miserable. The Smith family essentially relocated to the hospital, staying with him constantly.

But at the same time, their friends and family, as well as complete strangers, stepped up to offer help. A meal train was set up to provide the family with food, and prayers came from all directions.

A GoFundMe page has raised more than $36,000 for the family. A community Facebook page has more than 5,000 members.

"We had a rally of people come around us," Stephanie Smith said. "We couldnt have done it without all of the people who have come together."

Charlie has completed his first four rounds of chemotherapy, and on Jan. 20, he was able to return home with his family to wait for surgery to remove the tumor in his abdomen. That operation is tentatively going to be early to mid February.

In the meantime, the family has been soaking in the opportunity to be together somewhere besides the hospital. They have also been working to plan the blood drive being held on Saturday.

Charlie has relied on blood transfusions throughout his treatment, and a blood drive would be a way to raise awareness of the importance of those transfusions to cancer patients, Stephanie Smith said.

"Charlie received quite a few blood products, especially early on in his treatment. He had 12 transfusions in these 2 1/2 months. For his little body, thats a lot," she said. "Being a nurse, I didnt realize the number of cancer patients who need blood products. Its so important. So this was a way to let people know that."

Stephanie Smiths sister, Shelby Richards, knew people who had organized drives with their friends and helped the family get the Cheering for Charlie drive going.

The drive is a perfect opportunity to remind people that blood donations are vitally important, Brodt said. Versiti Blood Center of Indiana needs to collect at least 560 blood donations every day to support the need at its 80 hospital partners throughout the state, he said.

"So our Cheering for Charlie will truly make a difference and help save lives," Brodt said.

For the Smith family, the drive is a way to give back for all the love theyve been shown.

"Its really cool for us to see how many people have signed up, and also be advocates for other people who need blood, to just get the word out there about how important it is," Stephanie Smith said. "Its encouraging for us to see people come out to support Charlie and kids like him."

If you go

Cheering for Charlie blood drive

What: A blood drive honoring Charlie Smith, an 18-month-old Franklin child diagnosed with neuroblastoma, a cancer of the nerve cells.

When: 6 a.m. to 2 p.m. Saturday

Where: Versiti Blood Center of Indiana, 8739 U.S. 31 S., Indianapolis

Who can donate: Generally, anyone in good health age 16 and up can donate. Make sure you do not have a cold, flu or sore throat at the time of donation.

How to schedule an appointment: Go to Versiti.org/Indiana

Information: Learn more about Charlie on the Cheering for Charlie! Facebook group page.

Excerpt from:
Blood drive to honor Franklin child with cancer - Daily Journal

Bone Marrow Stem Cells Comments Off on Blood drive to honor Franklin child with cancer – Daily Journal | January 24th, 2020

(MENAFN - ForPressRelease) 11

New Delhi 23rd January 2020 On Saturday, January 18th, 2020, the Advancells Group & the International Fertility Center together ended their first workshop Sub-Specialty Training in Application of Regenerative Medicine (S.T.A.R. 2020). The three-day workshop had specialized doctors, medical practitioners, learned scientists of Advancells, the leaders in cell manufacturing & processes and IFC, one of India's most prestigious Fertility institute who were joined by candidates with MBBS/BAMS/BHMS/BPharma & Master's degree in Life Sciences.

The key-note speaker of the workshop was Dr. Rita Bakshi, founder and chairperson of International Fertility Centre, the oldest fertility clinic and one of the most renowned IVF clinics in India, one of the organizers of the event. Participants also had a privilege to listen to Dr. Sachin Kadam, CTO, Advancells and gain hands-on experience in the preparation of PRP; Liposuction method; and Bone Marrow aspiration. All these techniques were talked about at length and demonstrated in the form of manual & kit-based models to help the candidates gain exposure.

Dr. Punit Prabha, Head of Clinical Research and Dr. Shradha Singh Gautam, Head of Lab Operations at Advancells successfully set the base of stem cell biology for the participants who were experts in gynecology field, stem cell research and pain specialist. With the help of detailed analysis of 'Application of PRP for Skin rejuvenation'; 'Preparation of Micro-fragmented Adipose Tissue and Nano Fat & SVF (Stromal Vascular Fraction) from Adipose Tissue'; and 'Cell Culturing and Expansion in a Laboratory', applicants understood the application of stem cells in aesthetics, cosmetology, and anti-aging.

Vipul Jain, Founder & CEO of Advancells Group said, 'Educating young scientists about stem cells is important for us. With this workshop we wanted to discuss and share the challenges and lessons we have learned in our journey of curing our customers. We wanted to establish more concrete knowledge base in the presence of subject matter experts and help our attendees in more possible ways. We are hopeful to have successfully achieved what we claimed with this workshop'.

Given the resounding success of the Sub-Specialty Training in Application of Regenerative Medicine (S.T.A.R. 2020), it's hoped that the future events shall offer even greater wisdom to the participants by helping them improve and the lead the community into the age of greater awareness.

Advancells Group Advancells is leading the field of stem cell therapies in India and abroad, with representative offices in Bangladesh and Australia. The company provides arrangements for stem cell banking and protocols for partner doctors and hospitals which they can use for treating the patients using regenerative medicine. With a GMP compliant research and processing center that works on different cell lines from various sources such as Bone Marrow, Adipose Tissue, Dental Pulp, Blood, Cord Tissue etc. Advancells also intends to file a patent for this processing technology soon.

User :- Ajit Singh

Email :

Mobile:- 9953809503

MENAFN2401202000703206ID1099596615

Read the original:
Advancells Group & IFC Concluded their 3-Day Workshop on Regenerative Medicine - MENAFN.COM

Bone Marrow Stem Cells Comments Off on Advancells Group & IFC Concluded their 3-Day Workshop on Regenerative Medicine – MENAFN.COM | January 24th, 2020

ANI | Updated: Jan 23, 2020 17:49 IST

New Delhi [India], Jan 23 (ANI/Business Wire India): On Saturday, January 18 2020, the Advancells Group and the International Fertility Center together ended their first workshop - Sub-Specialty Training in Application of Regenerative Medicine (STAR 2020).The three-day workshop had specialized doctors, medical practitioners, learned scientists of Advancells, the leaders in cell manufacturing and processes and IFC, one of India's most prestigious Fertility institutes who were joined by candidates with MBBS/BAMS/BHMS/BPharma and Master's degree in Life Sciences.The key-note speaker of the workshop was Dr Rita Bakshi, founder and chairperson of International Fertility Centre, the oldest fertility clinic and one of the most renowned IVF clinics in India, one of the organizers of the event.Participants also had a privilege to listen to Dr Sachin Kadam, CTO, Advancells and gain hands-on experience in the preparation of PRP; Liposuction method; and Bone Marrow aspiration. All these techniques were talked about at length and demonstrated in the form of manual and kit-based models to help the candidates gain exposure.Dr Punit Prabha, Head of Clinical Research and Dr Shradha Singh Gautam, Head of Lab Operations at Advancells successfully set the base of stem cell biology for the participants who were experts in gynecology field, stem cell research and pain specialist.With the help of detailed analysis of 'Application of PRP for Skin rejuvenation'; 'Preparation of Micro-fragmented Adipose Tissue and Nano Fat & SVF (Stromal Vascular Fraction) from Adipose Tissue'; and 'Cell Culturing and Expansion in a Laboratory', applicants understood the application of stem cells in aesthetics, cosmetology, and anti-ageing."Educating young scientists about stem cells is important for us. With this workshop, we wanted to discuss and share the challenges and lessons we have learned in our journey of curing our customers," said Vipul Jain, founder and CEO of Advancells Group."We wanted to establish a more concrete knowledge base in the presence of subject matter experts and help our attendees in more possible ways. We are hopeful to have successfully achieved what we claimed with this workshop," he added. Given the resounding success of the Sub-Specialty Training in Application of Regenerative Medicine (STAR 2020), it's hoped that the future events shall offer even greater wisdom to the participants by helping them improve and the lead the community into the age of greater awareness.This story is provided by BusinessWire India. ANI will not be responsible in any way for the content of this article. (ANI/BusinessWire India)

Continued here:
Advancells Group, IFC concluded their three-day workshop on Regenerative Medicine - ANI News

Bone Marrow Stem Cells Comments Off on Advancells Group, IFC concluded their three-day workshop on Regenerative Medicine – ANI News | January 24th, 2020

Eric Stegers heart is full, although his liver is smaller by 60%.

Steger, a 50-year-old man from Sunnydale, California, affiliated with Chabad, was in Pittsburgh earlier this month fulfilling his dream of donating an entire lobe of his liver to help save the life of another.

The liver recipient, Conservative Rabbi Jeffrey Kurtz-Lendner, 53, said he feels like he has been given a second chance at life.

Get The Jewish Chronicle Weekly Edition by email and never miss our top storiesFree Sign Up

Kurtz-Lendner, who relocated to Pittsburgh from Iowa for the purpose of obtaining a transplant at UPMC, had been diagnosed with fatty liver cirrhosis, but the doctors did not know how serious it was until they were in the midst of the transplant.

I could have died before I got put onto a list, said Kurtz-Lendner, who, after the Jan. 7 surgery, is still recuperating but has been discharged from the hospital.

Steger, a math tutor at Foothill College in Northern California, has donated stem cells for a bone marrow transplant and platelets many times, and has been wanting to help save a life with one of his organs for years. He even traveled to Israel to donate a kidney, but was ultimately turned down because he had hypertension.

About a year ago, though, he saw a UPMC commercial airing in California that advertised the fact that it was now performing altruistic liver donations.

I decided to give it a try, said Steger.

He then got in touch with Chaya Lipschutz, an Orthodox woman from Brooklyn who donated a kidney to a stranger in 2005, and since then has made it her work to help others find kidney matches. She receives no money for her services.

Lipschutz had made the shidduch with the kidney patient in Israel for Steger that did not work out, he said.

As fate would have it, Lipschutz did know people who needed a live liver transplant. Steger was medically cleared for the procedure, but the first few people with whom he matched found other donors. Lipschutz then turned to message boards to post that she had an able and willing donor.

Now I was a solution in search of a problem, said Steger.

When Kurtz-Lendners sister in Teaneck, New Jersey, happened to see Lipschutzs post, the match was made.

Post-surgery, both donor and recipient are doing well.

Im feeling very positive, said Kurtz-Lendner, noting that full recovery from the procedure will take about a year. Two weeks ago, I was dying. Now, I have another 30 years.

He, his wife Robin, and his oldest daughter will remain in Pittsburgh for at least six months.

Kurtz-Lendner did not meet Steger until after the surgery, and sees him as an inspiration of a human being. I appreciate what he has done. He just saved my life.

Steger returned to California this week. During his time in Pittsburgh, he received warm hospitality from the citys Jewish community, particularly the Bikur Cholim of Pittsburgh, run by Nina Butler, he said.

Patients and families who come here from out of town always remind us of how special our community is, said Butler. As the Bikur Cholim of Pittsburgh, Im simply organizing the generosity of volunteers to provide the specific support that each patient wants. That started before Jeff or Eric arrived, answering their questions about housing, Shabbat observance and kosher food.

Eric is observant and came unaccompanied, so his housing was complicated because the Family House does not allow patients to stay completely alone, Butler explained. We provided home hospitality, and we also organized volunteers to drop off meals for Eric while his hosts were at work. Most of all, we formed relationships with both patients and Jeffs family so they knew there were Pittsburghers who had their backs.

Robin Kurtz-Lendner said that she and her husband felt so supported, even before we got here. Its been incredible. The whole community has been rallying around us and its really been appreciated.

Donating part of his liver was not easy, Steger acknowledged. Still, he wants to encourage others to consider organ donation.

Im not going to sugarcoat it, he said. It was the hardest thing Ive ever done. It was a year out of my life, one full year when I was thinking about this all the time.

There was a battery of tests, the surgery itself, and now the recovery phase, he said, which all carry physical and emotional risks.

But he is hoping what he did will help generate continued interest in organ donation.

I hope my experience will inspire other people to investigate it for themselves, he said.pjc

Toby Tabachnick can be reached atttabachnick@pittsburghjewishchronicle.org.

Link:
California man donates part of his liver to Conservative rabbi in Pittsburgh - The Australian Jewish News

Bone Marrow Stem Cells Comments Off on California man donates part of his liver to Conservative rabbi in Pittsburgh – The Australian Jewish News | January 24th, 2020

In 2019, the Stem Cell Therapy market is spectated to surpass ~US$ xx Mn/Bn with a CAGR of xx% over the forecast period. The Stem Cell Therapy market clicked a value of ~US$ xx Mn/Bn in 2018. Region is expected to account for a significant market share, where the Stem Cell Therapy market size is projected to inflate with a CAGR of xx% during the forecast period.

In the Stem Cell Therapy market research study, 2018 is considered as the base year, and 2019-2019 is considered as the forecast period to predict the market size. Important regions emphasized in the report include region 1 (country 1, country2), region 2 (country 1, country2), and region 3 (country 1, country2).

Request Sample Report @ https://www.tmrresearch.com/sample/sample?flag=B&rep_id=1787&source=atm

Global Stem Cell Therapy market report on the basis of market players

The report examines each Stem Cell Therapy market player according to its market share, production footprint, and growth rate. SWOT analysis of the players (strengths, weaknesses, opportunities and threats) has been covered in this report. Further, the Stem Cell Therapy market study depicts the recent launches, agreements, R&D projects, and business strategies of the market players including

Key Trends

The key factors influencing the growth of the global stem cell therapy market are increasing funds in the development of new stem lines, the advent of advanced genomic procedures used in stem cell analysis, and greater emphasis on human embryonic stem cells. As the traditional organ transplantations are associated with limitations such as infection, rejection, and immunosuppression along with high reliance on organ donors, the demand for stem cell therapy is likely to soar. The growing deployment of stem cells in the treatment of wounds and damaged skin, scarring, and grafts is another prominent catalyst of the market.

On the contrary, inadequate infrastructural facilities coupled with ethical issues related to embryonic stem cells might impede the growth of the market. However, the ongoing research for the manipulation of stem cells from cord blood cells, bone marrow, and skin for the treatment of ailments including cardiovascular and diabetes will open up new doors for the advancement of the market.

Global Stem Cell Therapy Market: Market Potential

A number of new studies, research projects, and development of novel therapies have come forth in the global market for stem cell therapy. Several of these treatments are in the pipeline, while many others have received approvals by regulatory bodies.

In March 2017, Belgian biotech company TiGenix announced that its cardiac stem cell therapy, AlloCSC-01 has successfully reached its phase I/II with positive results. Subsequently, it has been approved by the U.S. FDA. If this therapy is well- received by the market, nearly 1.9 million AMI patients could be treated through this stem cell therapy.

Another significant development is the granting of a patent to Israel-based Kadimastem Ltd. for its novel stem-cell based technology to be used in the treatment of multiple sclerosis (MS) and other similar conditions of the nervous system. The companys technology used for producing supporting cells in the central nervous system, taken from human stem cells such as myelin-producing cells is also covered in the patent.

Global Stem Cell Therapy Market: Regional Outlook

The global market for stem cell therapy can be segmented into Asia Pacific, North America, Latin America, Europe, and the Middle East and Africa. North America emerged as the leading regional market, triggered by the rising incidence of chronic health conditions and government support. Europe also displays significant growth potential, as the benefits of this therapy are increasingly acknowledged.

Asia Pacific is slated for maximum growth, thanks to the massive patient pool, bulk of investments in stem cell therapy projects, and the increasing recognition of growth opportunities in countries such as China, Japan, and India by the leading market players.

Global Stem Cell Therapy Market: Competitive Analysis

Several firms are adopting strategies such as mergers and acquisitions, collaborations, and partnerships, apart from product development with a view to attain a strong foothold in the global market for stem cell therapy.

Some of the major companies operating in the global market for stem cell therapy are RTI Surgical, Inc., MEDIPOST Co., Ltd., Osiris Therapeutics, Inc., NuVasive, Inc., Pharmicell Co., Ltd., Anterogen Co., Ltd., JCR Pharmaceuticals Co., Ltd., and Holostem Terapie Avanzate S.r.l.

Report available at a discounted price exclusively!!! Offer ends today!!!

Request For Discount On This Report @ https://www.tmrresearch.com/sample/sample?flag=D&rep_id=1787&source=atm

The Stem Cell Therapy market report answers the following queries:

The Stem Cell Therapy market report provides the below-mentioned information:

Customize This Report @ https://www.tmrresearch.com/sample/sample?flag=CR&rep_id=1787&source=atm

Research Methodology of Stem Cell Therapy Market Report

The global Stem Cell Therapy market study covers the estimation size of the market both in terms of value (Mn/Bn USD) and volume (x units). Both top-down and bottom-up approaches have been used to calculate and authenticate the market size of the Stem Cell Therapy market, and predict the scenario of various sub-markets in the overall market. Primary and secondary research has been thoroughly performed to analyze the prominent players and their market share in the Stem Cell Therapy market. Further, all the numbers, segmentation, and shares have been gathered using authentic primary and secondary sources.

Here is the original post:
Soaring Demand for Clean-label Food Products to Trigger the Growth of the Stem Cell Therapy Market 2017 2025 - Fusion Science Academy

Cardiac Stem Cells Comments Off on Soaring Demand for Clean-label Food Products to Trigger the Growth of the Stem Cell Therapy Market 2017 2025 – Fusion Science Academy | January 24th, 2020

Global Mafura Butter Market Report Market Size, Share, Price, Trends and Forecast is a professional and in-depth study on the current state of the global Mafura Butter industry.

The report also covers segment data, including: type segment, industry segment, channel segment etc. cover different segment market size, both volume and value. The compilation also covers information about clients from different industries, which is very important for the manufacturers.

There are 4 key segments covered in this Mafura Butter market report: competitor segment, product type segment, end use/application segment, and geography segment.

Request Sample Report @ https://www.marketresearchreports.biz/sample/sample/6309?source=atm

Quantifiable data:-

Geographically, this report studies the top producers and consumers, focuses on product capacity, production, value, consumption, market share and growth opportunity in these key regions, covering North America, Europe, China, Japan, Southeast Asia, India Companies

The information for each competitor includes:

* Company Profile

* Main Business Information

* SWOT Analysis

* Sales, Revenue, Price, and Gross Margin

* Market Share

Send Enquiry On This Report @ https://www.marketresearchreports.biz/sample/enquiry/264?source=atm

key players and product offerings

MRR.BIZ has been compiled in-depth market research data in the report after exhaustive primary and secondary research. Our team of able, experienced in-house analysts has collated the information through personal interviews and study of industry databases, journals, and reputable paid sources.

The report provides the following information:

Tailwinds and headwinds molding the markets trajectory Market segments based on products, technology, and applications Prospects of each segment Overall current and possible future size of the market

The main aim of the report is to:

MRR.BIZ is a leading provider of strategic market research. Our vast repository consists research reports, data books, company profiles, and regional market data sheets. We regularly update the data and analysis of a wide-ranging products and services around the world. As readers, you will have access to the latest information on almost 300 industries and their sub-segments. Both large Fortune 500 companies and SMEs have found those useful. This is because we customize our offerings keeping in mind the specific requirements of our clients.

Important key questions answered in Mafura Butter market report:

What will the market growth rate, overview, and analysis by type of global Mafura Butter in 2029?

What are the key factors affecting market dynamics? What are the drivers, challenges, and business risks in Mafura Butter market?

What is dynamics, this overview includes analysis of scope and price analysis of top manufacturers profiles?

What are the opportunities, risks, and the driving forces behind of Mafura Butter market? What are the major upstream raw materials sourcing and downstream buyers?

What is the business overview by type, applications, gross margin, and market shares?

What are the opportunities and threats faced by manufacturers in the global Mafura Butter market?

Check Discount On This Report @ https://www.marketresearchreports.biz/sample/checkdiscount/6309?source=atm

Excerpt from:
Polyaspartic Coatings Market Insights on Revenue Analysis and Competitive Intelligence Study By 2026 : Key Players are Covestro AG; The...

Cardiac Stem Cells Comments Off on Polyaspartic Coatings Market Insights on Revenue Analysis and Competitive Intelligence Study By 2026 : Key Players are Covestro AG; The… | January 24th, 2020